JAKARTA – The performance of PT Phapros Tbk (PEHA) slowed down in the first half (H1) of 2024 compared to the same period in 2023. The revenue and profit of this issuer reportedly shrank 33.71% and 738% year-on-year (yoy), respectively.

Based on Financial Report of H1 2024 quoted Thursday (5/6), sales were recorded at IDR 367.81 billion, down from IDR 554.91 billion in 2023. Its gross profit also dropped 41.70% yoy to IDR 162.50 billion from IDR 278.75 billion. Furthermore, it lost IDR 49.46 billion, in contrast with its profit in H1 2023 of IDR 7.74 billion.

The component of PEHA’s revenue in H1 2024 came from the segment of generic drugs bearing (OGB) products of IDR 245.5 billion, followed by ethical products of IDR 62.62 billion, over-the-counter drugs of IDR 51.32 billion, and toll manufacturing cooperation of IDR 8.40 billion.

For comparison, in the same period in 2023, OGB products brought in sales of IDR 301.38 billion, followed by ethical products of IDR 167.18 billion, OTC products of IDR 77.51 billion, and toll manufacturing cooperation of IDR 8.82 billion.

In the first half (H1) of 2024, users with contribution of over 10% of total sales were PT Anugrah Argon Medica of IDR 61.14 billion and PT Kimia Farma Trading & Distribution (KFTD) of IDR 258.92 billion. In the same period last year, KFTD’s purchase clocked up to IDR 483.28 billion.

As of July 2024, PEHA’s total shares were at 840 million, owned by PT Kimia Farma Tbk (KAEF) (56.77%), Masrizal A Syarief (10.349%), and the public of (32.877%). The number of shareholders reached 4,084, with the ultimate beneficial owner of the shares is the government. (LK/ZH)